Merck's JUVISYNC Receives FDA Approval as First Treatment for Type 2 Diabetes and High Cholesterol

Strategic Insights -

Merck has announced that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC, a new treatment for type 2 diabetes that combines two medications: sitagliptin, a glucose-lowering medication, and simvastatin, a cholesterol-lowering medication. This combination therapy is designed to help patients with type 2 diabetes who also need to lower their cholesterol levels. According to Barry J. Goldstein, M.D., Ph.D., vice president of Diabetes and Endocrinology at Merck, nearly 40 percent of eligible patients with type 2 diabetes do not receive statin treatment, despite clinical guidelines recommending it.

Key Takeaways:

  • JUVISYNC is the first treatment option that combines the glucose-lowering medication sitagliptin with the cholesterol-lowering medication simvastatin in one tablet.
  • The FDA approved JUVISYNC based on clinical bioequivalence studies in healthy subjects that demonstrated its efficacy in lowering blood sugar and cholesterol.
  • JUVISYNC is indicated for patients with type 2 diabetes who need glycemic and lipid therapy, and is contraindicated in patients with a history of serious hypersensitivity reactions, such as anaphylaxis or angioedema.
  • The risk of pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been reported in patients taking sitagliptin, and patients should be observed carefully for signs and symptoms of pancreatitis after initiation of JUVISYNC.
  • JUVISYNC should be administered to women of childbearing age only when they are highly unlikely to conceive, due to the risk of harm to the fetus.
  • The recommended dose of JUVISYNC is 100 mg (sitagliptin 100 mg + simvastatin) once daily, with the option to adjust the dose based on individual response.
  • JUVISYNC has not been studied in patients with a history of pancreatitis, and the risk of developing pancreatitis while taking JUVISYNC is unknown.

Statistics:

  • 40 percent of eligible patients with type 2 diabetes do not receive statin treatment.
  • The risk of pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking sitagliptin is unknown, but has been reported in postmarketing cases.

Sources:

  • Merck news release: "Merck Announces FDA Approval of JUVISYNC, the First Combination Therapy for the Treatment of Type 2 Diabetes and High Cholesterol"
  • FDA approval letter for JUVISYNC (sitagliptin and simvastatin)
  • Clinical bioequivalence studies in healthy subjects published in the Journal of Clinical Pharmacology